STAT

Opinion: You can’t tell a book by its cover — or a disease by Drake’s race

Diagnoses based on race are wrong on many levels.
A diagram of rapper Drake's parents is no way to study disease diagnosis.

In my first year of medical school, I walked into a study room to find a Venn diagram on the whiteboard. Underneath the title “Diseases Drake is at Risk for Developing” floated two intersecting circles, subtitled “Black Daddy” and “White Jewish Mommy.”

Drake is the multimillion-dollar rapper with the most charted songs for a solo artist in the history of the Billboard Hot 100. But on this whiteboard, he’s just a man with a Black Daddy and a White Jewish Mommy. What struck me was how crudely a hypothetical patient had been reduced to his race.

The diagram hadn’t been drawn — the brutal, nine-hour assessment that medical students must take before graduation. One of the time-saving tricks we learn is to associate race with disease. A black child under 10 years old? Sickle cell disease. An Asian patient with weak pulses? Takayasu’s vasculitis. Urban man of color? Think drug use or violent trauma. A Mexican patient with gastrointestinal distress? Parasites from contaminated water. A white newborn that hasn’t passed meconium? Bet on cystic fibrosis.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About AstraZeneca CEO Pay, Alternatives To WuXi And More
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.…
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

Related Books & Audiobooks